Glucose-dependent insulinotropic polypeptide reduces postprandial glucose excursions but does not protect from hypoglycaemia in persons with type 1 diabetes-A randomised placebo-controlled study

What Was Tested

This randomized controlled trial paper looks at GIP (Gastric Inhibitory Polypeptide).

To explore the glucose-stabilising potential of GIP in type 1 diabetes, the researchers evaluated the effects of exogenous and endogenous GIP on plasma glucose excursions in a setting of excess prandial insulin and physical activity after meal ingestion.

Who Took Part

The study group was 12 men.

The age groups tagged for this paper are young adults and adults, men only.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Random assignment meant chance, not the researchers, decided who got GIP (Gastric Inhibitory Polypeptide) and who got the comparison, which limits bias.

As a double-blind GIP (Gastric Inhibitory Polypeptide) study, the assignments were hidden from both participants and investigators until the end.

Some men received a placebo instead of GIP (Gastric Inhibitory Polypeptide), giving a reference point.

In the crossover set-up each of the men took both GIP (Gastric Inhibitory Polypeptide) and the comparison in turn, acting as their own control.

What Was Measured

Topics PubMed links to this paper include Gastric Inhibitory Polypeptide, Diabetes Mellitus, Type 1, Postprandial Period, Hypoglycemia, Blood Glucose, Insulin and Glucagon.

Author keywords: GIP receptor, antagonist, glucose‐dependent insulinotropic polypeptide, hypoglycaemia and type 1 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of GIP (Gastric Inhibitory Polypeptide) in 12 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Diabetes, obesity & metabolism), a journal based in England.

More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.